Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN 5% vs AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Amino acids provide substrates for protein synthesis, counteract negative nitrogen balance, and maintain muscle mass. Dextrose supplies calories for energy metabolism, and electrolytes correct or prevent imbalances.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
1-2 L/day intravenously, infused at a rate of 1-2 mL/kg/hour (50-100 mL/hour) for a 70 kg adult, adjusted based on nitrogen and caloric needs.
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Variable; amino acids have half-lives of minutes to hours depending on metabolic demand and renal function. Dextrose has a half-life of 15-20 minutes under normal conditions. In renal impairment, half-life of amino acid byproducts may prolong.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Urea (from amino acid metabolism) is excreted renally. Electrolytes and dextrose metabolites are eliminated via renal and respiratory routes. No significant biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution